Skip to content
Screener

AOCI at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
-$1.76B-2.8%
AptarGroup logo
AptarGroupATR
-$198.72M+43.4%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
-$7.83M+72.4%
AVT
AvantorAVTR
-$55.2M-431%
Dow logo
DowDOW
-$7.66B+2.1%
DuPont de Nemours, Inc. logo
DuPont de Nemours, Inc.DD
-$612M+51.5%

Other financials

Income statement

See full
Revenue$872.3M+13.8%
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$24.7B+44.8%
Enterprise value$24.58B+45.8%
P/E43.7×+8.7×
P/S7.4×+1.7×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.

The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000105770-26-000099
(in millions, except per share data)June 30,2026December 31,2025
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding
Common stock, par value $0.25 per share; 200.0 million shares authorized; shares issued: June 30, 2026 - 75.3 million, December 31, 2025 - 75.3 million; shares outstanding: June 30, 2026 - 70.4 million, December 31, 2025 - 72.0 million18.818.8
Capital in excess of par value
Retained earnings4,624.14,374.9
Accumulated other comprehensive loss(140.4)(105.5)
Treasury stock, at cost (June 30, 2026 - 4.9 million shares, December 31, 2025 - 3.3 million shares)(1,512.3)(1,112.2)
Total Equity2,990.23,176.0
Total Liabilities and Equity$4,076.4$4,270.0

Item 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is West Pharmaceutical Services's AOCI?
West Pharmaceutical Services (WST) reported AOCI of -$140.4M in Q2 2026.
How has West Pharmaceutical Services's AOCI changed year-over-year?
West Pharmaceutical Services's AOCI decreased by 58.3% year-over-year, from -$88.7M to -$140.4M.
What is the long-term trend for West Pharmaceutical Services's AOCI?
Over 5 years (2020 to 2025), West Pharmaceutical Services's AOCI has grown at a -0.9% compound annual growth rate (CAGR), from -$110.6M to -$105.5M.
What does AOCI mean?
Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.

Ask your AI about West Pharmaceutical Services's aoci.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude